Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ALPMY Stock Summary
Top 10 Correlated ETFs
ALPMY
In the News
US FDA declines to approve Astellas' gastric cancer drug
Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues related to a third-party manufacturer.
Astellas gets green light from European Commission for menopause drug
The European Commission has approved Astellas Pharma's fezolinetant, a non-hormonal treatment for managing moderate-to-severe vasomotor symptoms (VMS) like hot flashes and night sweats in menopausal women. This approval addresses a large unmet need, as up to 97% of women aged 40 to 64 in Europe experience these symptoms.
Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call November 1, 2023 3:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy & Relations Atsushi Kitamura - Chief Financial Officer Naoki Okamura - Representative Director, President & Chief Executive Officer Yoshitsugu Shitaka - Chief Scientific Officer Tadaaki Taniguchi - Chief Medical Officer Claus Zieler - Chief Commercial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Kazuaki Hashiguchi - Daiwa Securities Shinichiro Muraoka - Morgan Stanley MUFJ Securities Seiji Wakao - JPMorgan Securities Akinori Ueda - Goldman Sachs Securities Shinya Tsuzuki - Mizuho Securities Hiromitsu Ikeda Thank you very much for joining Astellas Pharma Inc.'s FY 2023 Second Quarter Financial Results Announcement meeting out of a very busy schedule. I'm delighted to serve us as moderator today.
New Strong Sell Stocks for October 2nd
ALPMY, BTDPY and ALRS have been added to the Zacks Rank #5 (Strong Sell) List on October 2, 2023.
New Strong Sell Stocks for September 26th
ALPMY, ASH and DHC have been added to the Zacks Rank #5 (Strong Sell) List on September 26, 2023.
New Strong Sell Stocks for September18th
ALPMY, CBRE and FMAO have been added to the Zacks Rank #5 (Strong Sell) List on September 18, 2023.
Astellas withdraws lawsuit challenging Medicare drug price negotiation plans
Japan-based Astellas Pharma on Wednesday withdrew a lawsuit filed against the U.S. government, days after its prostate cancer drug was spared from the first list of drugs that will be subject to Medicare price negotiations.
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen Inc. NASDAQ: AMGN were trading normally following news that their drugs would be subject to next year's Medicare price negotiations.
New Strong Sell Stocks for August 21st
ALPMY, CYRX and DRCT have been added to the Zacks Rank #5 (Strong Sell) List on August 21, 2023.
Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call August 1, 2023 4:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura - Representative Director, President and CEO Yoshitsugu Shitaka - Chief Scientific Officer Tadaaki Taniguchi - Chief Medical Officer Claus Zieler - Chief Commercial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Kazuaki Hashiguchi - Daiwa Securities Naomi Kumagai - Mitsubishi UFJ Morgan Stanley Securities Akinori Ueda - Goldman Sachs Securities Shinichiro Muraoka - Morgan Stanley MUFJ Securities Madoka Sato - Schroder Investment Management Kasumi Haruta - Credit Suisse Securities Shinya Tsuzuki - Mizuho Securities Hiromitsu Ikeda Thank you very much for your participation on this earning call for Q1 FY 2023 Financial Results Ended June 30, 2023. I am Ikeda, Head of Corporate Communications, serving as the moderator for today.
ALPMY Financial details
ALPMY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 676.2 | 693.34 | 672.83 | 700.74 | 834.4 | |
Net income per share | 115.05 | 104.15 | 64.93 | 67.08 | 54.24 | |
Operating cash flow per share | 135.32 | 119.42 | 165.78 | 139.57 | 182.59 | |
Free cash flow per share | 108.34 | 77.91 | 124.08 | 98.24 | 133.95 | |
Cash per share | 162.37 | 174.74 | 178.6 | 182.34 | 217.92 | |
Book value per share | 651.38 | 687.12 | 746.38 | 789.48 | 828.54 | |
Tangible book value per share | 312.04 | 152.51 | 242.67 | 288.61 | 339.03 | |
Share holders equity per share | 651.38 | 687.12 | 746.38 | 789.48 | 828.54 | |
Interest debt per share | 1.71 | 186.68 | 117.62 | 88.31 | 78.11 | |
Market cap | 3286.75B | 3064.02B | 3171.06B | 3531.45B | 3441.27B | |
Enterprise value | 2976.88B | 3158.96B | 3123.19B | 3428.21B | 3264.44B | |
P/E ratio | 14.79 | 15.68 | 26.3 | 28.46 | 34.86 | |
Price to sales ratio | 2.52 | 2.36 | 2.54 | 2.72 | 2.27 | |
POCF ratio | 12.57 | 13.67 | 10.3 | 13.68 | 10.36 | |
PFCF ratio | 15.7 | 20.96 | 13.76 | 19.43 | 14.12 | |
P/B Ratio | 2.61 | 2.38 | 2.29 | 2.42 | 2.28 | |
PTB ratio | 2.61 | 2.38 | 2.29 | 2.42 | 2.28 | |
EV to sales | 2.28 | 2.43 | 2.5 | 2.64 | 2.15 | |
Enterprise value over EBITDA | 8.66 | 9.13 | 9.65 | 11.44 | 8.35 | |
EV to operating cash flow | 11.39 | 14.1 | 10.14 | 13.28 | 9.82 | |
EV to free cash flow | 14.22 | 21.61 | 13.55 | 18.87 | 13.39 | |
Earnings yield | 0.07 | 0.06 | 0.04 | 0.04 | 0.03 | |
Free cash flow yield | 0.06 | 0.05 | 0.07 | 0.05 | 0.07 | |
Debt to equity | 0 | 0.27 | 0.16 | 0.11 | 0.09 | |
Debt to assets | 0 | 0.15 | 0.1 | 0.07 | 0.06 | |
Net debt to EBITDA | -0.9 | 0.27 | -0.15 | -0.34 | -0.45 | |
Current ratio | 1.72 | 1.09 | 1.47 | 1.34 | 1.45 | |
Interest coverage | 215.16 | 93.02 | 107.45 | 44.46 | 78.85 | |
Income quality | 1.18 | 1.15 | 2.55 | 2.08 | 3.37 | |
Dividend Yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | |
Payout ratio | 0.32 | 0.38 | 0.63 | 0.69 | 1.02 | |
Sales general and administrative to revenue | 0 | 0.38 | 0.4 | 0.42 | 0.42 | |
Research and developement to revenue | 0.16 | 0.17 | 0.18 | 0.19 | 0.18 | |
Intangibles to total assets | 0.35 | 0.43 | 0.41 | 0.4 | 0.36 | |
Capex to operating cash flow | -0.2 | -0.35 | -0.25 | -0.3 | -0.27 | |
Capex to revenue | -0.04 | -0.06 | -0.06 | -0.06 | -0.06 | |
Capex to depreciation | -0.82 | -1.17 | -1.07 | -0.96 | -0.84 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.3K | 1.27K | 1.04K | 1.09K | 1.01K | |
ROIC | 0.2 | 0.13 | 0.13 | 0.1 | 0.12 | |
Return on tangible assets | 0.18 | 0.15 | 0.09 | 0.09 | 0.06 | |
Graham Net | 11.51 | -183.72 | -110.88 | -83.94 | -71.66 | |
Working capital | 359.49B | 68.81B | 280.22B | 235.94B | 323.92B | |
Tangible asset value | 602.83B | 286.14B | 450.68B | 533.85B | 617.05B | |
Net current asset value | 217.91B | -158.49B | -14.93B | 51.27B | 101.39B | |
Invested capital | 0 | 0.27 | 0.16 | 0.11 | 0.09 | |
Average receivables | 345.33B | 366.67B | 363.88B | 380.58B | 424.89B | |
Average payables | 163.09B | 178.62B | 148.37B | 127.76B | 135.49B | |
Average inventory | 149.57B | 151.26B | 157.55B | 158.58B | 163.73B | |
Days sales outstanding | 101.35 | 103.99 | 104.33 | 113.77 | 107.14 | |
Days payables outstanding | 206.65 | 210.68 | 168.79 | 169.64 | 156.63 | |
Days of inventory on hand | 168.98 | 185.03 | 221.95 | 198.62 | 194.78 | |
Receivables turnover | 3.6 | 3.51 | 3.5 | 3.21 | 3.41 | |
Payables turnover | 1.77 | 1.73 | 2.16 | 2.15 | 2.33 | |
Inventory turnover | 2.16 | 1.97 | 1.64 | 1.84 | 1.87 | |
ROE | 0.18 | 0.15 | 0.09 | 0.08 | 0.07 | |
Capex per share | -26.98 | -41.51 | -41.7 | -41.33 | -48.65 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 220.68 | 195.77 | 209 | 218.73 | 235.2 | |
Net income per share | 26.56 | -25.49 | 18.46 | -0.81 | 8.09 | |
Operating cash flow per share | 40.26 | 65.25 | 7.59 | 22.35 | 29.59 | |
Free cash flow per share | 28.89 | 49.71 | -1.53 | 5.1 | 21.08 | |
Cash per share | 226.78 | 219.19 | 335.98 | 202.83 | 159.11 | |
Book value per share | 861.7 | 833.34 | 879.73 | 914.38 | 837.96 | |
Tangible book value per share | 345.58 | 341 | 352.42 | -165.67 | -187.89 | |
Share holders equity per share | 861.7 | 833.34 | 879.73 | 914.38 | 837.96 | |
Interest debt per share | 3.94 | 77.71 | 201.6 | 497.46 | 487.09 | |
Market cap | 3608.51B | 3421.44B | 3862.73B | 3721.01B | 3009.03B | |
Enterprise value | 3375.43B | 3244.61B | 3660.24B | 4377.44B | 3725.7B | |
P/E ratio | 18.64 | -18.54 | 29.15 | -637.6 | 51.83 | |
Price to sales ratio | 8.97 | 9.66 | 10.3 | 9.49 | 7.13 | |
POCF ratio | 49.18 | 28.98 | 283.73 | 92.84 | 56.69 | |
PFCF ratio | 68.54 | 38.04 | -1.41K | 407.16 | 79.59 | |
P/B Ratio | 2.3 | 2.27 | 2.45 | 2.27 | 2 | |
PTB ratio | 2.3 | 2.27 | 2.45 | 2.27 | 2 | |
EV to sales | 8.39 | 9.16 | 9.76 | 11.16 | 8.83 | |
Enterprise value over EBITDA | 30.23 | 42.49 | 41.86 | 58.05 | 42.98 | |
EV to operating cash flow | 46 | 27.48 | 268.86 | 109.22 | 70.19 | |
EV to free cash flow | 64.12 | 36.07 | -1.33K | 478.98 | 98.54 | |
Earnings yield | 0.01 | -0.01 | 0.01 | 0 | 0 | |
Free cash flow yield | 0.01 | 0.03 | 0 | 0 | 0.01 | |
Debt to equity | 0 | 0.09 | 0.23 | 0.54 | 0.58 | |
Debt to assets | 0 | 0.06 | 0.13 | 0.25 | 0.26 | |
Net debt to EBITDA | -2.09 | -2.32 | -2.32 | 8.71 | 8.27 | |
Current ratio | 1.52 | 1.45 | 1.33 | 0.96 | 0.91 | |
Interest coverage | 31.63 | 25.74 | 23.6 | 16.06 | 14.03 | |
Income quality | 1.52 | -2.56 | 0.41 | -27.47 | 3.66 | |
Dividend Yield | 0.02 | 0 | 0.01 | 0 | 0.02 | |
Payout ratio | 1.13 | 0 | 1.63 | 0 | 4.32 | |
Sales general and administrative to revenue | 0.41 | 0.45 | 0.45 | 0.46 | 0.47 | |
Research and developement to revenue | 0.17 | 0.2 | 0.17 | 0.2 | 0.18 | |
Intangibles to total assets | 0.37 | 0.36 | 0.34 | 0.55 | 0.55 | |
Capex to operating cash flow | -0.28 | -0.24 | -1.2 | -0.77 | -0.29 | |
Capex to revenue | -0.05 | -0.08 | -0.04 | -0.08 | -0.04 | |
Capex to depreciation | -0.9 | -1.22 | -0.7 | -0.79 | -0.33 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 717.6 | 691.33 | 604.55 | 129.39 | 390.55 | |
ROIC | 0.04 | 0.03 | 0.02 | 0 | 0.01 | |
Return on tangible assets | 0.03 | -0.03 | 0.02 | 0 | 0.01 | |
Graham Net | -55.64 | -72.07 | -88.45 | -588.31 | -606.25 | |
Working capital | 366.69B | 323.92B | 325.96B | -45.5B | -103.61B | |
Tangible asset value | 629.82B | 617.05B | 632.31B | -297.03B | -337.06B | |
Net current asset value | 129.07B | 101.39B | 97.91B | -786.92B | -815.33B | |
Invested capital | 0 | 0.09 | 0.23 | 0.54 | 0.58 | |
Average receivables | 463.23B | 454.36B | 461.5B | 490.91B | 505.25B | |
Average payables | 140.38B | 137.24B | 139.34B | 142.84B | 148.84B | |
Average inventory | 165.93B | 168.8B | 187.31B | 206.94B | 219.81B | |
Days sales outstanding | 103.6 | 113.25 | 114.53 | 115.81 | 107.91 | |
Days payables outstanding | 144.46 | 176.42 | 159.71 | 133.76 | 124.97 | |
Days of inventory on hand | 175.66 | 219.38 | 230.98 | 194.08 | 187.73 | |
Receivables turnover | 0.87 | 0.79 | 0.79 | 0.78 | 0.83 | |
Payables turnover | 0.62 | 0.51 | 0.56 | 0.67 | 0.72 | |
Inventory turnover | 0.51 | 0.41 | 0.39 | 0.46 | 0.48 | |
ROE | 0.03 | -0.03 | 0.02 | 0 | 0.01 | |
Capex per share | -11.38 | -15.54 | -9.12 | -17.26 | -8.51 |
ALPMY Frequently Asked Questions
What is Astellas Pharma Inc. stock symbol ?
Astellas Pharma Inc. is a JP stock and trading under the symbol ALPMY
What is Astellas Pharma Inc. stock quote today ?
Astellas Pharma Inc. stock price is $10.94 today.
Is Astellas Pharma Inc. stock public?
Yes, Astellas Pharma Inc. is a publicly traded company.